Bank of New Hampshire’s Ascendis Pharma A/S ASND Stock Holding History

Bank of New Hampshire’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.2K	Buy	+72	New	+$16.8K	﹤0.01%	413

Other funds holding ASND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Bank of New Hampshire's ASND Position: Q2 2026 in Review

Bank of New Hampshire opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 72 shares worth $19.2K. The stake represents ﹤0.01% of the portfolio and ranks #413 among its holdings.

107 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bank of New Hampshire held 72 shares of Ascendis Pharma A/S worth $19.2K as of Q2 2026.
Ascendis Pharma A/S was a new Bank of New Hampshire position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Bank of New Hampshire's portfolio in Q2 2026, its #413 holding.
107 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bank of New Hampshire's 13F filing for Q2 2026, filed 14 Jul 2026.